Open AccessMental health interventions for rifampicin-resistant tuberculosis patients with alcohol use disorders, Zhytomyr, Ukraine
Author(s) -
Vitalii Plokhykh,
Marve Duka,
Laurel Cassidy,
ChungYu Chen,
Khachatur Malakyan,
Petros Isaakidis,
Dimitri Donchuk,
Nune Truzyan,
Anthony Reid,
Olha Siomak,
M. V. Pogrebna,
Nataliia Lytvinenko
Publication year - 2021
Publication title -
journal of infection in developing countries
Language(s) - English
Resource type - Journals
eISSN - 2036-6590
pISSN - 1972-2680
DOI - 10.3855/jidc.13827
Subject(s) - medicine , tuberculosis , cohort , psychological intervention , depression (economics) , alcohol use disorder , cohort study , rifampicin , quality of life (healthcare) , culture conversion , psychiatry , alcohol , biochemistry , chemistry , pathology , economics , macroeconomics , nursing , sputum
Despite concerted efforts, Ukraine is challenged by increasing rates of multidrug and rifampicin-resistant tuberculosis (MDR/RR-TB) comorbid with alcohol use disorder (AUD). This study describes a cohort of RR-TB patients with high alcohol consumption treated in MSF Zhytomyr Project, Ukraine.
Methodology: We used programmatic data for 73 RR-TB patients screened with the AUD Identification Test March-July 2019 and followed-up for culture conversion/TB treatment outcome till 31 January 2020. We described socio-demographic, behavioral, and clinical characteristics, the level of depressive symptoms, and TB treatment outcomes in three groups: 1) patients with AUD who received mental health interventions (MHI); 2) patients with AUD who did not receive MHI; 3) patients with no AUD. We also found three potential contributors to declining to receive MHI.
Results: Main characteristics of the study groups did not differ substantially. Those receiving MHI (mean: nine sessions) were rated for alcohol consumption as ‘hazardous’ (41%), ‘harmful’ (43%) and ‘dependence’ (36%) and had higher depression scores versus the second (p=0.009) and third (p=0.095) groups at baseline. Depressive symptoms declined at 9-month follow-up for all patients. Culture conversion was seen at 77%, 73%, and 83% for each group respectively. We also found three reasons for declining from MHI.
Conclusions: We detected little differences across the groups. However, our study cohort demonstrated substantially higher adherence rates, culture conversion and reduction of depressive symptoms than reported globally. We recommend further research on the effectiveness of MHI in changing the drinking habits, quality of life and/or TB treatment outcomes of patients with AUD.